Neurocrine Biosciences | NBIX - Selling And Administration Expenses


Neurocrine Biosciences reported $366.3M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
ALKERMES USD 190.54M 6.1M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Cytokinetics USD 113.14M 8.75M Sep/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Exelixis USD 154.56M 6.93M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Incyte USD 364.27M 12.54M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Prothena USD 10.9M 1.77M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Repligen USD 83.59M 6.97M Sep/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026